Swiss National Bank raised its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 1.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,600 shares of the medical equipment provider’s stock after purchasing an additional 700 shares during the period. Swiss National Bank owned 157,394.84% of ABIOMED worth $11,735,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Scout Investments Inc. increased its stake in ABIOMED by 3.3% in the third quarter. Scout Investments Inc. now owns 551,949 shares of the medical equipment provider’s stock valued at $93,059,000 after purchasing an additional 17,706 shares in the last quarter. Principal Financial Group Inc. increased its stake in ABIOMED by 2.7% in the third quarter. Principal Financial Group Inc. now owns 178,768 shares of the medical equipment provider’s stock valued at $30,140,000 after purchasing an additional 4,716 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in ABIOMED by 2.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 15,023 shares of the medical equipment provider’s stock valued at $2,533,000 after purchasing an additional 397 shares in the last quarter. DE Burlo Group Inc. bought a new stake in ABIOMED in the third quarter valued at $2,849,000. Finally, American Century Companies Inc. increased its stake in ABIOMED by 99.8% in the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock valued at $81,626,000 after purchasing an additional 241,868 shares in the last quarter. 90.74% of the stock is owned by hedge funds and other institutional investors.
ABMD has been the subject of several research analyst reports. Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price target for the company in a research note on Monday, October 30th. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Piper Jaffray Companies reissued a “buy” rating and set a $160.00 target price on shares of ABIOMED in a research report on Tuesday, August 29th. SunTrust Banks, Inc. reissued a “buy” rating and set a $195.00 target price on shares of ABIOMED in a research report on Wednesday, November 1st. Finally, Jefferies Group LLC boosted their target price on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $185.38.
Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at $194.32 on Monday. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The company has a market cap of $8,590.00, a PE ratio of 124.56, a PEG ratio of 2.59 and a beta of 0.23. ABIOMED, Inc. has a 52-week low of $103.53 and a 52-week high of $198.29.
ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. research analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current year.
In related news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the transaction, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Eric A. Md Rose sold 982 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $145.17, for a total transaction of $142,556.94. Following the transaction, the director now owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,646 shares of company stock worth $8,456,680. 7.00% of the stock is owned by corporate insiders.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.